The American Brain Coalition (ABC) is a non-profit organization comprising many of the United States’ leading patient advocacy and voluntary health organizations, as well as professional neurological, psychological, and psychiatric associations. We also enjoy the support of a small number of publicly-traded corporations that actively engage in brain-related research. Together, we seek to advance the understanding of brain functions and reduce the burden of brain disorders through public advocacy with the Congress, the administration, and the general public.
- ABC provides a strong and powerful voice for the 50 million people with disabling brain disorders, bringing together organizations that represent concerned and interested patients, families, and professionals. We advocate for:
- Increased support of research that will lead to better treatment,
Services and support that will improve patients’ quality of life, and,
A national commitment toward finding cures for individuals with disabling neurological and psychological disorders.
Through its lobbying and advocacy efforts, ABC raises awareness among policymakers about the causes, impacts, and consequences of neurologic and psychiatric illness. Our broad advocacy focus appeals to all member groups whether it be advocating for sufficient funding, allocations for biomedical research at the National Institutes of Health (NIH is seeking to improve the health care system to better serve people with chronic illnesses); searching for new and effective ways to continue to address the cost, availability and quality of care; and promoting the understanding of the responsible use of animals in research and its importance to groundbreaking discoveries that lead to more successful treatments of brain disorders.
Together with Reps. Cathy McMorris Rodgers (R-WA) and Earl Blumenauer (D-OR), ABC hosts a series of Congressional Neuroscience Caucus briefings for the U.S. Congress members and staff to foster the understanding of how the brain develops, functions, and ages. The Caucus also seeks to educate lawmakers and the public about the millions of Americans afflicted with neurological disorders or mental illness.
ABC is uniquely positioned to act as a forum for professional non-profit, corporate and patient advocacy groups and to encourage the development of coordinated activities on a shared agenda.
Join our effort today!
DCX-expressing cells in the subgranular zone. Column A, C, D shows normal conditions, column B, D, F shows conditions after induction of seizures by kainate application. A and C, DCX-positive cells in the subgranular zone (SGZ) with dendrites of various lengths reaching into the molecular layer. The nucleus appears usually devoid of immunoreaction. The granule cell layer is seen as a light band. Scale bar (in B for all panels), 150 μm. Insert, high power depiction of a cluster of DCX-positive cells of different morphology. Scale bar, 45 μm. B and D, Kainate application increases the number of DCX-positive cells in the SGZ (here at 10 days after seizure induction). Scale bar, 150 μm. E and F, Kainate injections increase the number of DCX-positive cells but do not seem to cause abnormal growth of the apical dendrites. Scale bar, 80 μm. Plümpe et al. BMC Neuroscience 2006 7:77 doi:10.1186/1471-2202-7-77 via Wikimedia Commons